Adeno-Associated Viral Delivery of GDNF Promotes Recovery of Dopaminergic Phenotype following a Unilateral 6-Hydroxydopamine Lesion

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cell Transplantation

• Publication date

  2002-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3727/096020198389988PMID 12075987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Time course of degenerative alterations in nigral dopaminergic neurons following a 6‐hydroxydopamine lesion

  2000cited by this paper
• Dopamine transporter‐immunoreactive neurons decrease with age in the human substantia nigra

  1999cited by this paper
• Restorative gene therapy approaches to Parkinson's disease.

  1999cited by this paper
• GDNF Protection against 6-OHDA–Induced Reductions in Potassium-Evoked Overflow of Striatal Dopamine

  1999cited by this paper
• Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.

  1999cited by this paper
• Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias.

  1999cited by this paper
• GDNF

  1999cited by this paper
• Cell death of dopamine neurons in aging and Parkinson's disease.

  1999cited by this paper
• Etiology of Parkinson's Disease

  1999cited by this paper
• Lentiviral gene transfer to the nonhuman primate brain.

  1999cited by this paper
• Highly Purified Recombinant Adeno-Associated Virus Vectors Are Biologically Active and Free of Detectable Helper and Wild-Type Viruses

  1999cited by this paper
• GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys.

  1999cited by this paper
• Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat

  1999cited by this paper
• Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates.

  1998cited by this paper
• Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases.

  1998cited by this paper
• Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic L-Amino Acid Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors

  1998cited by this paper
• Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys

  1998cited by this paper
• Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

  1998cited by this paper
• Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies.

  1998cited by this paper
• Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.

  1997cited by this paper
• Glial cell line-derived neurotrophic factor improves survival of ventral mesencephalic grafts to the 6-hydroxydopamine lesioned striatum

  1997cited by this paper
• Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease.

  1997cited by this paper
• Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.

  1997cited by this paper
• Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy

  1997cited by this paper
• 霊長類パｰキンソン病モデルにおける Glial Cell Line-Derived Neurotrophic Factor (GDNF) とレボドｰパの相互作用について

  1997cited by this paper
• The effect of the catecholamine precursor L‐Dopa on sleep bruxism: A controlled clinical trial

  1997cited by this paper
• On the question of apoptosis in the parkinsonian substantia nigra

  1997cited by this paper
• Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

  1997cited by this paper
• Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

  1997cited by this paper
• GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis

  1997cited by this paper
• Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.

  1997cited by this paper
• Applications of gene therapy to the CNS.

  1996cited by this paper
• Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

  1996cited by this paper
• Functional recovery in parkinsonian monkeys treated with GDNF

  1996cited by this paper
• Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease

  1996cited by this paper
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

  1996cited by this paper
• 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat

  1996cited by this paper
• Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

  1995cited by this paper
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995cited by this paper
• Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys

  1995cited by this paper
• GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

  1995cited by this paper
• [Neuronal transplantation in animal models of Parkinson disease: in vivo voltammetry, tissue cryopreservation and immunology].

  1995cited by this paper
• Cell Lines for the Production of Recombinant Adeno-Associated Virus

  1995cited by this paper
• Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons

  1995cited by this paper
• Reduced expression of the molecular markers of dopaminergic neuronal atrophy in the aging rat brain.

  1995cited by this paper
• Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms.

  1995cited by this paper
• The cryptic life style of adenoassociated virus

  1995cited by this paper
• Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase

  1994cited by this paper
• Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

  1994cited by this paper
• Practical considerations for the use of the optical disector in estimating neuronal number.

  1994cited by this paper
• Gene delivery into the brain using virus vectors

  1993cited by this paper
• An adenovirus vector for gene transfer into neurons and glia in the brain

  1993cited by this paper
• Adenovirus vectors enter the brain.

  1993cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• The genetics of Parkinson's disease. A review.

  1993cited by this paper
• Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.

  1993cited by this paper
• A 16-Channel Automated Rotometer System for Reliable Measurement of Turning Behavior in 6-Hydroxydopamine Lesioned and Transplanted Rats

  1993cited by this paper
• Calbindin‐D28K in the basal ganglia of patients with parkinsonism

  1992cited by this paper
• Occupational and environmental causes of parkinsonism.

  1992cited by this paper
• Manipulation of adenovirus vectors.

  1991cited by this paper
• Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells.

  1991cited by this paper
• Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types

  1988cited by this paper
• Adeno-associated virus general transduction vectors: analysis of proviral structures

  1988cited by this paper
• Some new, simple and efficient stereological methods and their use in pathological research and diagnosis

  1988cited by this paper
• A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication

  1987cited by this paper
• Latent infection of KB cells with adeno-associated virus type 2

  1986cited by this paper
• A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase

  1984cited by this paper
• The etiology of Parkinson's disease.

  1970cited by this paper
• Parkinson's disease. I.

  1970cited by this paper
• Parkinson's disease. II.

  1970cited by this paper
• Pseudoxanthoma elasticum

  1970cited by this paper
• Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system.

  1970cited by this paper

• Long-term benefits of hematopoietic stem cell-based macrophage/microglia delivery of GDNF to the CNS in a mouse model of Parkinson’s disease

  2024cites this paper
• Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

  2024cites this paper
• Gene delivery for Parkinson's disease

  2020cites this paper
• GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration

  2018cites this paper
• Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice.

  2015cites this paper
• Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy

  2015cites this paper
• Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways

  2014cites this paper
• RESTORATION OF MOTOR AND NON-MOTOR FUNCTIONS BY NEUROTROPHIC FACTORS IN NONHUMAN PRIMATES WITH DOPAMINE DEPLETION

  2013cites this paper
• Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).

  2013cites this paper
• Translating the therapeutic potential of neurotrophic factors to clinical 'proof of concept': a personal saga achieving a career-long quest.

  2012cites this paper
• The enhancement of neural stem cell survival and growth by coculturing with expanded sertoli cells in vitro

  2012cites this paper
• Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.

  2011cites this paper
• Neurotrophic factor therapy for Parkinson's disease.

  2010cites this paper
• The current status of gene therapy for Parkinson's disease

  2010cites this paper
• Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

  2010cites this paper
• Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model

  2009cites this paper
• Emerging restorative treatments for Parkinson's disease.

  2008cites this paper
• Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.

  2007cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2007cites this paper
• [Gene therapy for Parkinson's disease].

  2007cites this paper
• TARGETING AXON GROWTH FROM NEURONS TRAN SPLANTEDINTO THE CENTRAL NER VOUS SYSTEM

  2007cites this paper
• Enhancing tyrosine hydroxylase expression and survival of fetal ventral mesencephalon neurons with rat or porcine Sertoli cells in vitro.

  2006cites this paper
• Progress and development in Parkinson disease therapy

  2006cites this paper
• In vivo gene therapy as a potential treatment for Parkinson's disease

  2006cites this paper
• Gene Therapy Applications for Parkinson’s Disease

  2006cites this paper
• Gene therapy for Parkinson’s disease using recombinant adeno-associated viral vectors

  2005cites this paper
• Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age.

  2005cites this paper
• 3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicity

  2005cites this paper
• Gene therapy in Parkinson’s disease

  2004cites this paper
• Intraparenchymal delivery of GDNF towards a treatment for Parkinson ’ s disease Review Article

  2004cites this paper
• [Stromal cell transplant in the 6-OHDA lesion model].

  2004cites this paper
• Co‐transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6‐hydroxydopamine‐lesioned rats: implications for Parkinson's disease

  2004cites this paper
• N. Pavón-Fuentes, L. Blanco-Lezcano, L. Martínez-Martín, L. Castillo-Díaz, K. de la Cuétara-Bernal, R. García-Miniet, L. Lorigados-Pedre, Y. Coro-Grave de Peralta, A. García-Varona, J.C. Rosillo-Martí, R. Macías-González

  2004cites this paper
• The potential of GDNF as a treatment for Parkinson's disease.

  2004cites this paper
• Gene therapy progress and prospects: Parkinson's disease

  2003cites this paper
• Cell Transplantation: The Regenerative Medicine Journal. A biennial analysis of publications.

  2003cites this paper
• Article Commentary: Cell Transplantation: The Regenerative Medicine Journal. A Biennial Analysis of Publications

  2003cites this paper
• Making connections: the development of mesencephalic dopaminergic neurons.

  2003cites this paper
• [Pharmacological targets in neurodegenerative diseases].

  2003cites this paper
• Dianas farmacológicas en las enfermedades neurodegenerativas

  2003cites this paper
• Gene transfer to the nervous system: prospects for novel treatments directed at diseases of the aging nervous system.

  2003cites this paper
• Emerging Strategies in Neural Transplantation and Repair: A Special Issue Based on the Eighth Annual Conference

  2002cites this paper
• Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain.

  2002cites this paper
• Adeno-associated virus vectors for gene transfer to the brain.

  2002cites this paper